KRAS and lung carcinoma: In human lung cancer cells, ISRIB acted in a dose-dependent manner to increase DUSP6 and decrease p-ERK in TG-treated H23 and H358 cells with KRAS G12C but not in H1299 and H1703 cells with WT KRAS (Fig. 5b).